CRISPR Therapeutics AG (CRSP) EBT (2015 - 2026)

CRISPR Therapeutics AG has disclosed EBT across 12 years of filings, most recently posting -$122.1 million for Q1 2026.

• EBT for Q1 2026 came in at -$122.1 million, up 9.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $45.3 million (up 104.04% YoY), and the FY2025 annual result was $32.5 million, down 21.11% from the prior year.
• EBT came in at -$122.1 million for Q1 2026 at CRISPR Therapeutics AG, down from $480.5 million in the prior quarter.
• In the past five years, EBT ranged from a high of $480.5 million in Q4 2025 to a low of -$207.3 million in Q2 2025.
• The 5-year median for EBT is -$115.9 million (2024), against an average of -$50.0 million.
• Peak annual rise in EBT reached 310.01% in 2024, while the deepest fall reached 123.92% in 2024.
• CRISPR Therapeutics AG's EBT stood at -$120.1 million in 2022, then soared by 174.62% to $89.6 million in 2023, then jumped by 310.01% to $367.3 million in 2024, then jumped by 30.82% to $480.5 million in 2025, then plunged by 125.41% to -$122.1 million in 2026.
• The last three EBT figures came in at -$122.1 million (Q1 2026), $480.5 million (Q4 2025), and -$105.8 million (Q3 2025), per Business Quant data.